You should reconsider if you believed that the days of “fat jabs” were over.
A new generation of GLP-1 drugs, such as Ozempic and Wegovy, is stealthily progressing through clinical studies and, in certain circumstances, being sold in the shadow of the black market, just as the world has started to come to terms with them.
Despite not yet being FDA-approved or accessible to the general public, these so-called “GLP-3” medications are creating a concerning amount of attention.
As a doctor and the creator of a lifespan and peptide-based weight loss program, I have personally witnessed the transformational power of GLP-1s for those battling obesity. I am also aware of the risks associated with using medications that haven’t been thoroughly tested.
What are GLP-3s, then? To put it simply, they are the next generation of metabolic medications that are intended to produce outcomes that are not possible with the weight-loss tablets and injections available today.
GLP-1 drugs are very successful for improving metabolic health, lowering cardiovascular risk, and lowering inflammation in addition to helping people lose weight. These drugs function by imitating a hormone that controls hunger and delays the emptying of the stomach. They are transformative for a lot of patients.
By tackling many metabolic pathways at once, GLP-3s—a moniker rather than a technical classification—seek to expand on that basis. Consider them as a shift from a single-tool strategy to a multi-tool one.
A new generation of GLP-1 drugs, such as Ozempic and Wegovy, is subtly progressing through clinical trials at the same time that the world has started to understand them.
Retatrutide is the GLP-3 medication that is now receiving the most interest. It operates on three distinct hormone receptors, including those affected by GLP-1 medications and an extra one known as glucagon, making it a “triple agonist.”
In essence, glucagon helps the body burn more calories while decreasing appetite by increasing energy expenditure.
According to preliminary clinical trials, retatrutide promotes weight reduction outcomes that are comparable to or even better than those of GLP-1 medications. In certain trials, GLP-3s patients lost up to 20 to 25 percent of their body weight, while GLP-1s patients lost between 10 and 20 percent. That starts to resemble bariatric surgery, but without the operating room.
Caution is necessary because it sounds almost too good to be true. Because some medications may have a more severe adverse effect profile despite their remarkable efficacy.
Similar to the adverse effects of GLP-1s, but maybe more severe, we are witnessing increased incidence of nausea, vomiting, and gastrointestinal distress.
Long-term safety is still a concern, especially in light of the inclusion of glucagon activity, which may have unidentified effects on metabolism and heart rate.
The crucial thing is that these medications are currently undergoing clinical studies. The FDA has not authorised them. Legal medical channels do not offer them. However, patients are already figuring out how to obtain them.
Demand, social media buzz, and the promise of quick, dramatic weight loss have all contributed to the emergence of a burgeoning black market.
I cannot emphasise this enough: it is risky to receive these drugs outside of approved systems. Purity, dosage accuracy, or even that the substance you are injecting is what you believe it to be are not guaranteed.
I’ve already started talking to patients in my practice who are enquiring about these medications and, in certain situations, acknowledging that they have attempted to find them online. This is the point at which education becomes essential.
This pattern is not new to us. GLP-1s that were not FDA-approved, off-label medication use, and now completely unapproved GLP-3s.
Retatrutide is the GLP-3 medication that is now receiving the most interest. Being a “triple agonist,” it affects three distinct hormone receptors.
NazarianSkin and Nazarian Plastic Surgery were founded by Dr. Sheila Nazarian.
The public’s understanding of these medications is growing faster than the patient protection measures put in place.
The FDA’s clearance is probably still a few years away. Clinical trials must continue, long-term data must be assessed, and safety profiles must be precisely defined. It is realistic to anticipate that these medications may hit the market in the latter half of this decade if the results continue to be positive. However, the future is not over yet.
We are seeing the start of a new chapter in the history of obesity medicine, one in which therapies are becoming more individualised, effective, and diverse.
Combinations that are specific to each person’s metabolic profile or drugs that not only encourage weight loss but also maintain muscle mass and improve general health may soon be available.
It may seem nearly unthinkable to patients who have been astounded by the outcomes of existing GLP-1 medications, as many of us have.
And yet, here we are.
The assurance is genuine. However, the hazards are also present.
As is always the case in medicine, the objective is to advance responsibly rather than merely.
